Loading
A phase 2 trial of Abiraterone acetate, Enzalutamide in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) is a phase 2 interventional study registered as NCT06991556 by Novartis Pharmaceuticals, with 168 participants enrolled, started 2025-07-07 and due to reach its primary completion in 2032-02-13. Interventions recorded: JSB462, Abiraterone, Enzalutamide. Conditions listed: Metastatic Hormone-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Metastatic hormone-sensitive prostate cancer, Abiraterone acetate, Novartis, Prostate cancer.
Shares Abiraterone acetate, Novartis, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Novartis, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Enzalutamide, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Enzalutamide, Prostate cancer.
Shares Enzalutamide, Novartis, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Prostate cancer.